Clinical trial
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
NCT00017862 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00017862 |
|---|---|
| Title | Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome |
| Official title | A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | SCH55700 |
| Enrollment | 10 |
| Start date | Jun 1, 2001 |
| Completion | Jun 1, 2003 |
| First posted | Apr 29, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: